Sectra completes acquisition of Oxipit

Sectra has completed its acquisition of Oxipit, a Lithuanian developer of autonomous AI for radiology. The company said the deal strengthens its portfolio of regulatory-approved AI tools for diagnostic imaging.

With the deal closed, Sectra now owns and plans to further develop ChestLink, Oxipit’s flagship product. Sectra described the software as an autonomous AI tool for chest X-ray analysis.

ChestLink automatically identifies and clears high-confidence normal chest X-rays from the radiology worklist, according to Sectra. The company said this allows radiologists to focus on cases with a higher probability of disease.

Sectra said the product holds CE Class IIb certification for autonomous chest X-ray analysis. The certification permits commercialization within the European Economic Area, according to the company.

In March, Sectra said Oxipit’s products were already deployed across multiple international markets. Oxipit’s portfolio includes CE-marked AI tools spanning chest X-ray, CT, and musculoskeletal imaging.

Financial terms were not disclosed. Sectra said in March that the acquisition would be financed using its own funds and was not expected to materially affect group sales or operating profit for the current year.

Oxipit’s team will operate as a dedicated AI development center within Sectra’s Imaging IT Solutions business area, according to the earlier acquisition announcement. Sectra said its Amplifier service will remain an open, vendor-neutral AI marketplace.